Weighted Average Number of Shares Outstanding, Diluted of Avalo Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Avalo Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 14,000,451, a 30% increase year-over-year.
  • Avalo Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 7,496,389, a 2599% increase from 2023.
  • Avalo Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 277,727, a 608% increase from 2022.
  • Avalo Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 39,202.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Avalo Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 14,000,451 +3,216,414 +30% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 10,829,760 +3,176,458 +42% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 10,514,901 +9,655,520 +1124% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 7,496,389 +7,218,662 +2599% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 10,784,037 +10,589,186 +5435% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 7,653,302 +7,595,085 +13046% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 859,381 +810,536 +1659% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 277,727 +238,525 +608% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 194,851 -9,218,781 -98% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 58,217 -9,342,685 -99% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 48,845 -9,350,673 -99% 01 Jan 2023 31 Mar 2023 10-Q/A 11 Jul 2024 2024 Q1
Q4 2022 39,202 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 9,413,632 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 9,400,902 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 9,399,518 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q3 2018 34,648,641 +13,240,939 +62% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q3 2017 21,407,702 +12,651,309 +144% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q3 2016 8,756,393 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3

Avalo Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 7,496,389 +7,218,662 +2599% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 277,727 +238,525 +608% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 39,202 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2018 34,773,613 +16,018,814 +85% 01 Jan 2018 31 Dec 2018 10-K 18 Mar 2019 2018 FY
2017 18,754,799 +9,924,403 +112% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 8,830,396 +6,604,373 +297% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 2,226,023 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.